Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Trog IV push data

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on Feb 16, 2022 2:54pm

87 Views

Post# 34434896

RE:RE:RE:RE:Trog IV push data

Well they had something to announce to some cherry picked investors in January! You seem to be of the opinion that everything is either black or white and nothing in between the reality is the exact opposite.

jfm1330 wrote: They break the silence when they have something to annouce.

SABBOBCAT wrote: Sniff, sniff ... I smell a financing... TH only breaks silence this frequently when they need money